BridgeBio Pharma BBIO EBITDA margin
EBITDA margin at other companies
Other financials
Where this comes from
Calculated from BridgeBio Pharma’s reported figures.
Based on trailing twelve months.
The official record: BridgeBio Pharma’s 10-Q, filed May 7, 2026, on SEC EDGAR. View the filing →
Ask your AI about BridgeBio Pharma's ebitda margin.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is BridgeBio Pharma's EBITDA margin?
- BridgeBio Pharma (BBIO) reported EBITDA margin of -89.6% in Q1 2026.
- How has BridgeBio Pharma's EBITDA margin changed year-over-year?
- BridgeBio Pharma's EBITDA margin increased by 83.5% year-over-year, from -543% to -89.6%.
- What is the long-term trend for BridgeBio Pharma's EBITDA margin?
- Over 4 years (2021 to 2025), BridgeBio Pharma's EBITDA margin has grown at a -40.4% compound annual growth rate (CAGR), from -818.7% to -103.2%.
- What does EBITDA margin mean?
- Operating cash profitability per sales dollar, before interest, taxes, and non-cash charges.
- How do you interpret EBITDA margin?
- Useful for comparing operating profitability across firms with different depreciation policies and leverage. High EBITDA margin alongside heavy capex can still mean weak free cash flow — pair it with FCF margin.
- How does EBITDA margin compare across companies?
- Widely used to compare capital-intensive businesses on a like-for-like basis. Less meaningful for banks and insurers.